Sungsoon Fang

US Patent:

20200123113, Apr 23, 2020

Filed:

Sep 10, 2019

Appl. No.:

16/566343

Inventors:

- La Jolla CA, US
- New South Wales, AU
Annette Atkins - San Diego CA, US
Sungsoon Fang - La Jolla CA, US
Jae Myoung Suh - San Diego CA, US
Thomas J. Baiga - Escondido CA, US
Ruth T. Yu - La Jolla CA, US
John F.W. Keana - Eugene OR, US
Christopher Liddle - Chertswood, AU

Assignee:

Salk Institute for Biological Studies - La Jolla CA
The University of Sydney - New South Wales

International Classification:

C07D 231/56
C07B 59/00
C07C 233/63

Abstract:

Novel compounds having a formulaembodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

US Patent:

20190084939, Mar 21, 2019

Filed:

Nov 27, 2018

Appl. No.:

16/200861

Inventors:

- La Jolla CA, US
- New South Wales, AU
Annette Atkins - San Diego CA, US
Sungsoon Fang - La Jolla CA, US
Jae Myoung Suh - San Diego CA, US
Thomas J. Baiga - Escondido CA, US
Ruth T. Yu - La Jolla CA, US
John F.W. Keana - Eugene OR, US
Christopher Liddle - Chertswood, AU

Assignee:

Salk Institute for Biological Studies - La Jolla CA
The University of Sydney - Sydney

International Classification:

C07D 231/56
C07C 233/63
C07B 59/00

Abstract:

Novel compounds having a formulaembodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

US Patent:

20170066724, Mar 9, 2017

Filed:

Sep 12, 2016

Appl. No.:

15/263033

Inventors:

- La Jolla CA, US
- Sydney, AU
Annette Atkins - San Diego CA, US
Sungsoon Fang - La Jolla CA, US
Jae Myoung Suh - San Diego CA, US
Thomas J. Baiga - Escondido CA, US
Ruth T. Yu - La Jolla CA, US
John F.W. Keana - Eugene OR, US
Christopher Liddle - Chertswood, AU

Assignee:

Salk Institute for Biological Studies - La Jolla CA
The University of Sydney - Sydney

International Classification:

C07D 231/56
C07B 59/00
C07C 233/63

Abstract:

Novel compounds having a formulaembodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

US Patent:

20150258052, Sep 17, 2015

Filed:

Mar 13, 2015

Appl. No.:

14/657078

Inventors:

- La Jolla CA, US
- Ann Arbor MI, US
Annette Atkins - San Diego CA, US
Sungsoon Fang - La Jolla CA, US
Jae Myoung Suh - San Diego CA, US
Ruth T. Yu - La Jolla CA, US
Alan R. Saltiel - Ann Arbor MI, US

Assignee:

Salk Institute for Biological Studies - La Jolla CA
The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 31/216
A61K 31/137
A61K 31/4704
A61K 9/00
A61K 45/06

Abstract:

Provided are methods of promoting browning of white adipose tissue (WAT) in a subject. Such methods can include administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of fexaramine in combination with a therapeutically effective amount of a compound that mimics or increases sympathetic nervous system activity (e.g., one or more beta-adrenergic agonists and/or compounds that increase epinephrine secretion).